Provectus Biopharma (NYSE:PVCT) was the recipient of a large decline in short interest during the month of September. As of September 30th, there was short interest totalling 1,821,793 shares, a decline of 26.7% from the September 15th total of 2,487,008 shares. Based on an average daily volume of 4,033,468 shares, the days-to-cover ratio is presently 0.5 days. Currently, 0.9% of the company’s stock are short sold.

Provectus Biopharma (NYSE:PVCT) opened at 0.071 on Wednesday. The stock’s market cap is $15.11 million. Provectus Biopharma has a 52-week low of $0.07 and a 52-week high of $0.56. The stock has a 50 day moving average price of $0.11 and a 200 day moving average price of $0.29.

Provectus Biopharma Company Profile

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Provectus Biopharmaceuticals, Inc is a development-stage biopharmaceutical company. The Company is engaged in developing pharmaceuticals for oncology and dermatology indications. The Company is focused on developing its prescription drug candidates, PV-10 and PH-10. It is developing PV-10 for treatment of several life threatening cancers, including metastatic melanoma, liver cancer and breast cancer.

5 Day Chart for NYSE:PVCT

Receive News & Ratings for Provectus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provectus Biopharma and related companies with's FREE daily email newsletter.